



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/550,363	04/15/2007	Elaine Alison Irving	PB60024USw	6175
23347	7590	09/04/2009	EXAMINER	
GLAXOSMITHKLINE			KOLKER, DANIEL E	
CORPORATE INTELLECTUAL PROPERTY, MAI B482			ART UNIT	PAPER NUMBER
FIVE MOORE DR., PO BOX 13398			16-49	
RESEARCH TRIANGLE PARK, NC 27709-3398			NOTIFICATION DATE	DELIVERY MODE
			09/04/2009	ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USCIPRTP@GSK.COM  
LAURA.M.MCCULLEN@GSK.COM  
JULIE.D.MCFALLS@GSK.COM



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10550363	4/15/2007	IRVING ET AL.	PB60024USw
EXAMINER			
GLAXOSMITHKLINE			DANIEL KOLKER
CORPORATE INTELLECTUAL PROPERTY, MAI B482			
FIVE MOORE DR., PO BOX 13398			
RESEARCH TRIANGLE PARK, NC 27709-3398			
ART UNIT		PAPER	
1649		20090831	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Claims 17 and 18 are drawn to methods of using SEQ ID NO:18 and 19 respectively. These sequences appear in the specification (p. 26 line 36 - p. 27 line 14 and Figure 4) and claims as originally filed. However, neither the paper copy of the sequence listing nor the computer readable form (CRF) contain these sequences. The paper copy and the CRF each end at SEQ ID NO:17. In order to search claims which recite these sequences, a revised paper and CRF sequence listing must be submitted, as well as the required statements that the two are the same and that they do not introduce new matter. The examiner regrets that this issue was not brought up in the previous communication, however it was not apparent that claims which recite sequences did not have sequences in the paper or CRF listing.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

/Daniel E. Kolker/  
Primary Examiner, Art Unit 1649